US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Filana Therapeutics

0.9300

-0.0310-3.23%

Post-market: 0.93370.0037+0.40%16:06 EDT

Volume:121.62K

Turnover:114.13K

Market Cap:44.93M

PE:-1.06

High:0.9507

Open:0.9499

Low:0.9201

Close:0.9610

52wk High:4.98

52wk Low:0.8513

Shares:48.31M

Float Shares:47.32M

Volume Ratio:0.42

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8752

EPS(LYR):-1.8836

ROE:-55.78%

ROA:-7.14%

PB:0.71

PE(LYR):-0.49

Loading ...

Overview Company News Filings

Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate

Benzinga Earnings

Filana Therapeutics Q2 FY26 Net Loss Narrows 80.55% to $8.6 Million

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

THOMSON REUTERS

Filana Therapeutics shareholders approved 2018 incentive plan amendment at annual meeting

Filana Therapeutics posts Eilat XVIII scientific presentation on simufilam in TSC seizures

Filana Therapeutics Price Target Announced at $5.00/Share by Maxim Group

Filana Therapeutics resumed with a Buy at Maxim

Filana Therapeutics posts corporate presentation on simufilam development for TSC-related epilepsy

Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate

Benzinga Earnings

Filana Q1 net loss narrows to $10.3 million; R&D expenses fall 67% to $4.5 million

Press Release: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

Filana Therapeutics presents TSC-related epilepsy program at Eilat XVIII conference

Filana Therapeutics director Michael O'Donnell to resign after annual meeting

Filana Therapeutics announces annual stockholders meeting webcast

Filana Therapeutics publishes simufilam preclinical data

Filana publishes preclinical data showing simufilam slows seizure progression in TSC mice

Filana Therapeutics management to meet with Maxim

Cassava Sciences FY 2025 net loss rises 274% to USD 91 million, R&D expenses fall 62% to USD 26.6 million

Filana Therapeutics, Inc Qtrly EPS $-0.26

THOMSON REUTERS

Filana Therapeutics, Inc: Estimates Net Cash Use in Operations for First Half of 2026 in Range From $14 to $17 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/FLNA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FLNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FLNA\",,,,,undefined,":{"symbol":"FLNA","market":"US","secType":"STK","nameCN":"Filana Therapeutics","latestPrice":0.93,"timestamp":1787601600000,"preClose":0.961,"halted":0,"volume":121616,"hourTrading":{"tag":"盘后","latestPrice":0.9337,"preClose":0.93,"latestTime":"16:06 EDT","volume":115,"amount":106.9681999,"timestamp":1787601995254,"change":0.0037,"changeRate":0.003978,"amplitude":0.003978},"delay":0,"changeRate":-0.03225806451612895,"floatShares":47317539,"shares":48307896,"eps":-0.875208,"marketStatus":"Post-Mkt","change":-0.031,"latestTime":"08-24 16:08:55 EDT","open":0.9499,"high":0.9507,"low":0.9201,"amount":114126.6921344,"amplitude":0.031842,"askPrice":1.01,"askSize":100,"bidPrice":0.91,"bidSize":18,"shortable":3,"etf":0,"ttmEps":-0.875208,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.961,"preHourTrading":{"tag":"盘前","latestPrice":0.9499,"preClose":0.961,"latestTime":"09:26 EDT","volume":152,"amount":143.3999008,"timestamp":1787577999843,"change":-0.0111,"changeRate":-0.01155,"amplitude":0.010406},"postHourTrading":{"tag":"盘后","latestPrice":0.9337,"preClose":0.93,"latestTime":"16:06 EDT","volume":115,"amount":106.9681999,"timestamp":1787601995254,"change":0.0037,"changeRate":0.003978,"amplitude":0.003978},"volumeRatio":0.422374,"impliedVol":2.0812,"impliedVolPercentile":0.9043},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FLNA\",,,,,undefined,":{"symbol":"FLNA","floatShares":47317539,"roa":"-7.14%","roe":"-55.78%","lyrEps":-1.883615,"volumeRatio":0.422374,"shares":48307896,"dividePrice":0,"high":0.9507,"amplitude":0.031842,"preClose":0.961,"low":0.9201,"week52Low":0.8513,"pbRate":"0.71","week52High":4.98,"institutionHeld":0.341,"latestPrice":0.93,"committee":-0.694915,"eps":-0.875208,"divideRate":0,"volume":121616,"delay":0,"ttmEps":-0.875208,"open":0.9499,"prevYearClose":1.98,"prevWeekClose":0.961,"prevMonthClose":1.01,"prevQuarterClose":1.19,"fiveDayClose":0.89,"twentyDayClose":0.9004,"sixtyDayClose":1.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FLNA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-29","symbol":"FLNA","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785297600000,"reportTimeType":"pre","actualEps":-0.18},{"market":"US","date":"2026-05-07","symbol":"FLNA","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.21},{"market":"US","date":"2026-03-12","symbol":"FLNA","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FLNA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FLNA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1779854400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FLNA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FLNA","date":"2026-08-21","current":-1.098025,"percent":0.099099,"low":-1.176848,"twenty":-0.988871,"median":-0.854932,"eighty":-0.743564,"high":-0.548743,"avg":-0.861258,"sd":0.142216,"marketCap":45530191},"quantilePoints":[{"date":"2026-03-13","current":-1.035476,"twenty":-1.018822,"median":-0.993842,"eighty":-0.968861,"marketCap":94200397},{"date":"2026-03-20","current":-0.971755,"twenty":-1.052469,"median":-1.035476,"eighty":-0.980251,"marketCap":88403449},{"date":"2026-03-27","current":-0.939894,"twenty":-1.035476,"median":-0.99034,"eighty":-0.956117,"marketCap":85504975},{"date":"2026-04-02","current":-0.913343,"twenty":-1.035476,"median":-0.971755,"eighty":-0.913343,"marketCap":83089581},{"date":"2026-04-10","current":-0.913343,"twenty":-1.014236,"median":-0.950514,"eighty":-0.897413,"marketCap":83089581},{"date":"2026-04-17","current":-0.934584,"twenty":-0.998305,"median":-0.926619,"eighty":-0.886793,"marketCap":85021896},{"date":"2026-04-24","current":-0.881482,"twenty":-0.982375,"median":-0.918653,"eighty":-0.886793,"marketCap":80191107},{"date":"2026-05-01","current":-0.76997,"twenty":-0.971755,"median":-0.908033,"eighty":-0.860242,"marketCap":70046449},{"date":"2026-05-08","current":-0.722178,"twenty":-0.971755,"median":-0.897413,"eighty":-0.828381,"marketCap":65698738},{"date":"2026-05-15","current":-0.768948,"twenty":-0.952207,"median":-0.889448,"eighty":-0.793752,"marketCap":59901791},{"date":"2026-05-22","current":-0.799954,"twenty":-0.950514,"median":-0.881482,"eighty":-0.768948,"marketCap":62317185},{"date":"2026-05-29","current":-0.961185,"twenty":-0.950853,"median":-0.881482,"eighty":-0.769766,"marketCap":74877238},{"date":"2026-06-05","current":-0.868167,"twenty":-0.950853,"median":-0.884138,"eighty":-0.774113,"marketCap":67631054},{"date":"2026-06-12","current":-0.812356,"twenty":-0.942018,"median":-0.880569,"eighty":-0.790031,"marketCap":63283343},{"date":"2026-06-18","current":-0.750344,"twenty":-0.936708,"median":-0.870862,"eighty":-0.769561,"marketCap":58452554},{"date":"2026-06-26","current":-0.719338,"twenty":-0.931941,"median":-0.860242,"eighty":-0.763894,"marketCap":56037159},{"date":"2026-07-02","current":-0.775149,"twenty":-0.929817,"median":-0.854932,"eighty":-0.756545,"marketCap":60384870},{"date":"2026-07-10","current":-0.737942,"twenty":-0.927155,"median":-0.843362,"eighty":-0.756545,"marketCap":57486396},{"date":"2026-07-17","current":-0.669729,"twenty":-0.921847,"median":-0.823469,"eighty":-0.744143,"marketCap":52172527},{"date":"2026-07-24","current":-0.578075,"twenty":-0.918653,"median":-0.812356,"eighty":-0.737942,"marketCap":45032620},{"date":"2026-07-31","current":-1.096868,"twenty":-0.922912,"median":-0.812356,"eighty":-0.737942,"marketCap":46375580},{"date":"2026-08-07","current":-1.095725,"twenty":-0.938832,"median":-0.823469,"eighty":-0.737942,"marketCap":46327272},{"date":"2026-08-14","current":-1.080758,"twenty":-0.959945,"median":-0.843362,"eighty":-0.739037,"marketCap":45694438},{"date":"2026-08-21","current":-1.076873,"twenty":-0.988871,"median":-0.854932,"eighty":-0.743564,"marketCap":45530191}],"updateTime":1787568243073},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FLNA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655860857","title":"Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860857","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655860857?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:04","pubTimestamp":1785326668,"startTime":"0","endTime":"0","summary":"Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 18.18 percent. This is a 80.43 percent increase over losses of $(0.92) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60756874/filana-therapeutics-q2-eps-0-18-beats-0-23-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655867047","title":"Filana Therapeutics Q2 FY26 Net Loss Narrows 80.55% to $8.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655867047","media":"Reuters","labels":["policyRegulatory","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655867047?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:04","pubTimestamp":1785326647,"startTime":"0","endTime":"0","summary":"Filana Therapeutics Q2 FY26 net loss narrows 80.55% to $8.6 millionFilana Therapeutics posted a GAAP net loss of USD 8.6 million, or USD 0.18 per share, in Q2 2026, narrowing from USD 44.2 million.R&D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL6BRZbp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655672148","title":"Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655672148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655672148?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:00","pubTimestamp":1785326402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA5LS1PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643717272","title":"Filana Therapeutics shareholders approved 2018 incentive plan amendment at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643717272","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643717272?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:24","pubTimestamp":1781519072,"startTime":"0","endTime":"0","summary":"Filana Therapeutics held its annual shareholder meeting on June 11, 2026.Shareholders adopted an amendment to the 2018 Omnibus Incentive Plan, lifting authorized shares to 9,000,000 and extending the plan through Jan. 31, 2030.The amendment also bars option or SAR repricing, replacement, or cash-outs without shareholder approval, while tightening annual equity award limits.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL5Rh2sX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638631677","title":"Filana Therapeutics posts Eilat XVIII scientific presentation on simufilam in TSC seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2638631677","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638631677?lang=en_us&edition=fundamental","pubTime":"2026-05-28 05:43","pubTimestamp":1779918182,"startTime":"0","endTime":"0","summary":"Filana Therapeutics published a scientific conference presentation outlining simufilam development for tuberous sclerosis complex-associated seizures.Program targets filamin A modulation; presentation cites animal-model data showing reduced seizure activity in TSC and focal cortical dysplasia type II models.Document highlights prior safety database in Alzheimer’s trials, covering more than 1,900 patients across two placebo-controlled studies with no emerging safety signals.Preliminary Phase 2 proof-of-concept design described for ages 12-50, comparing 100 mg BID vs 200 mg BID with seizure-count reduction as a key endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to gen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL9mVMWk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540340","title":"Filana Therapeutics Price Target Announced at $5.00/Share by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540340?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FLNA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 16:02 ET (20:02 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638512628","title":"Filana Therapeutics resumed with a Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2638512628","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638512628?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:40","pubTimestamp":1779799215,"startTime":"0","endTime":"0","summary":"Maxim resumed coverage of Filana Therapeutics (FLNA) with a Buy rating and $5 price target Published first on TheFly – the ultimate source for real...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-resumed-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-resumed-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633178486","title":"Filana Therapeutics posts corporate presentation on simufilam development for TSC-related epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2633178486","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633178486?lang=en_us&edition=fundamental","pubTime":"2026-05-08 02:51","pubTimestamp":1778179912,"startTime":"0","endTime":"0","summary":"Filana Therapeutics outlined plan to develop simufilam for tuberous sclerosis complex-related epilepsy, positioning drug as potential first-in-class oral filamin A modulator.Program remains on FDA clinical hold following December 2025 letter; work underway to address requests for additional preclinical data and protocol modifications ahead of a response.Preclinical package cited anti-seizure activity across two mouse models, including 60% reduction in seizure frequency in Yale RhebCA model.Company highlighted safety database of more than 2,000 prior simufilam-treated subjects, with some exposed up to 24 months.Method-of-treatment patent issued in 2025 was in-licensed from Yale; product supply described as in place for planned proof-of-concept study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL3TwhDh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633449871","title":"Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633449871","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633449871?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:06","pubTimestamp":1778155572,"startTime":"0","endTime":"0","summary":"Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 56.25 percent increase over losses of $(0.48) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52362962/filana-therapeutics-q1-eps-0-21-beats-0-23-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144349","title":"Filana Q1 net loss narrows to $10.3 million; R&D expenses fall 67% to $4.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144349","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144349?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:04","pubTimestamp":1778155497,"startTime":"0","endTime":"0","summary":"Filana Therapeutics posted a net loss of USD 10.3 million, or USD 0.21 per share, narrowing from a loss of USD 23.4 million, or USD 0.48 per share, a year earlier.R&D expense fell 67% to USD 4.5 million, reflecting the phase-out of the Alzheimer’s disease development program completed in Q2 2025.G&A expense dropped 39% to USD 6.6 million, as legal loss contingencies recorded in Q1 2025 were not repeated.Cash and cash equivalents ended March 31, 2026 at USD 86.6 million, down from USD 95.5 million at year-end, with net cash used in operations of USD 8.9 million.Management said it is working to address the FDA’s clinical hold on simufilam in TSC-related epilepsy, including additional preclinical data and protocol design changes, while estimating cash at June 30, 2026 in a range of USD 47 million to USD 50 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLNShBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","BK4585","NDAQ","FLNA","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144331","title":"Press Release: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144331?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155200,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, May 07, 2026  -- Filana Therapeutics, Inc. , a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex -related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.\"2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are--a team dedicated to rigorous science and to bringing new treatment options to patients with TSC-related epilepsy and their families,\" said Rick Barry, President and Chief Executive Officer of Filana Therapeutics, Inc. \"We believe the recent publication of preclinical data in Epilepsia and our presentation at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices further support the biological rationale behind simufilam and our approach to the potential treatment of TSC-related ep","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA","BK4588","LABU","IND","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633910683","title":"Filana Therapeutics presents TSC-related epilepsy program at Eilat XVIII conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910683","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910683?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:03","pubTimestamp":1777982611,"startTime":"0","endTime":"0","summary":"Filana Therapeutics presented its TSC-related epilepsy program at Eilat XVIII, antiepileptic drugs and devices conference in Madrid.Presentation outlined biological rationale for clinical development evaluating simufilam in TSC-related epilepsy, with work continuing to address FDA clinical hold issued in December 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL3xL1cF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA","BK4112","BK4007","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631053390","title":"Filana Therapeutics director Michael O'Donnell to resign after annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631053390","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631053390?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:07","pubTimestamp":1777406870,"startTime":"0","endTime":"0","summary":"Filana Therapeutics director Michael O'Donnell plans to resign from board at conclusion of 2026 annual meeting of stockholders.O'Donnell will remain on board until resignation takes effect.Departure was not tied to any disagreement with Filana, management, or board over operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL6sF5XG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631981533","title":"Filana Therapeutics announces annual stockholders meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2631981533","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631981533?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:06","pubTimestamp":1777406814,"startTime":"0","endTime":"0","summary":"Filana Therapeutics scheduled 2026 annual shareholder meeting for June 11, 2026, to be held virtually.Shareholders will vote to elect or re-elect Richard J. Barry, Pierre Gravier, Claude Nicaise as Class II directors for three-year terms.Ballot includes Amendment No. 2 to 2018 Omnibus Incentive Plan, raising authorized shares to 9,000,000 from 5,000,000.Items also include ratification of Ernst & Young as independent auditor for fiscal 2026.Advisory vote scheduled on 2025 executive compensation for named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLbV4pGp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627728456","title":"Filana Therapeutics publishes simufilam preclinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2627728456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627728456?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:20","pubTimestamp":1776255615,"startTime":"0","endTime":"0","summary":"Filana Therapeutics (FLNA) announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a well-a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-publishes-simufilam-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-publishes-simufilam-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627281489","title":"Filana publishes preclinical data showing simufilam slows seizure progression in TSC mice","url":"https://stock-news.laohu8.com/highlight/detail?id=2627281489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627281489?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:04","pubTimestamp":1776254675,"startTime":"0","endTime":"0","summary":"Filana Therapeutics disclosed April 15, 2026 publication in Epilepsia of preclinical results for simufilam in a severe mouse model of TSC-related epilepsy.Study results were previously presented as top-line findings in August 2025.Data showed simufilam slowed worsening of seizure activity versus vehicle, supporting continued development in TSC-related epilepsy.Company is working to resolve an FDA clinical hold disclosed in December 2025, with a program update expected in coming months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL5fdJyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","BK4007","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","BK4112","NDAQ","FLNA","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620275272","title":"Filana Therapeutics management to meet with Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275272","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620275272?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:25","pubTimestamp":1773948318,"startTime":"0","endTime":"0","summary":"Meeting to be held on March 24-25 hosted by Maxim. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618413458","title":"Cassava Sciences FY 2025 net loss rises 274% to USD 91 million, R&D expenses fall 62% to USD 26.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618413458","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618413458?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:16","pubTimestamp":1773317771,"startTime":"0","endTime":"0","summary":"Cassava Sciences, now operating as Filana Therapeutics, reported a FY 2025 net loss of USD 91 million, compared with a FY 2024 net loss of USD 24.3 million. Cash and cash equivalents were USD 95.5 million as of Dec. 31, 2025, down 26% from the prior year-end, with no debt. FY 2025 R&D expenses fell 62% to USD 26.6 million, primarily due to the phase-out of the Alzheimer’s program, while FY 2025 G&A expenses were USD 68.8 million. Net cash used in operations was USD 32.3 million in FY 2025, and the company forecast first-half 2026 net cash use in operations of USD 14-17 million plus a USD 31.25 million payment tied to an estimated securities litigation settlement contingency. CEO Rick Barry said the company is working to address FDA requests related to a clinical hold letter received in December 2025, including additional pre-clinical data and protocol design modifications.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL5dCDsd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SAVA","BK4585","BK4547","FLNA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618797131","title":"Filana Therapeutics, Inc Qtrly EPS $-0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2618797131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618797131?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316807,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUA2C8G9K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131244","title":"Filana Therapeutics, Inc: Estimates Net Cash Use in Operations for First Half of 2026 in Range From $14 to $17 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131244?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUA2C8G9K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FLNA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}